PRODUCTS

On July 23, 2012, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (active ingredient: aclidinium bromide) for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD)-related bronchospasm (pulmonary gas). Narrowing of the tract), including chronic bronchitis and emphysema. COPD is a serious lung disease that causes breathing difficulties in patients. According to the information from the National Heart, Lung, and Blood Institute of the United States, smoking is the main cause of the disease. In the United States, COPD is the fourth leading cause of death. Symptoms in patients with the disease include chest suffocation, prolonged cough, and phlegm. Tudorza Pressair is a long-acting anticholinergic dry powder inhalation medicine, applied twice a day to improve the passage of airflow by relieving the muscles around the large airways of the lungs.

Three randomized, placebo-controlled, confirmatory trials have proved the safety and effectiveness of Tudorza Pressair. The trial included 1276 patients over 40 years of age who were diagnosed with COPD. These patients had a history of smoking at least one pack of cigarettes per day for up to 10 years. Years. Tudorza Pressair may cause serious adverse reactions, including abnormal bronchospasm, increased or worsened intraocular pressure (narrow-angle glaucoma), new or worsened urinary retention. The drug should not be used to treat acute respiratory problems (acute bronchospasm), and it is not recommended for patients younger than 18 years of age. The most common adverse reactions reported included headache, nasopharyngitis and cough.